Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 118Precursor Cell Lymphoblastic Leukemia-Lymphoma 116Lymphoma, Non-Hodgkin 108Leukemia, Lymphocytic, Chronic, B-Cell 100Multiple Myeloma 99Leukemia 96Lymphoma, Large B-Cell, Diffuse 95Lymphoma, Follicular 95Hodgkin Disease 94Lymphoma 93Lymphoma, Mantle-Cell 88Myelodysplastic Syndromes 84Lymphoma, Large-Cell, Immunoblastic 82Burkitt Lymphoma 78Lymphoma, B-Cell, Marginal Zone 71Leukemia, Myeloid, Accelerated Phase 65Leukemia, Myeloid, Chronic-Phase 64Congenital Abnormalities 63Myeloproliferative Disorders 62Leukemia, Myelomonocytic, Chronic 52Blast Crisis 51Neoplasms, Plasma Cell 49Waldenstrom Macroglobulinemia 44Recurrence 40Lymphoma, T-Cell, Cutaneous 40Primary Myelofibrosis 37Sezary Syndrome 36Mycosis Fungoides 36Lymphoma, Large-Cell, Anaplastic 32Myelodysplastic-Myeloproliferative Diseases 31

Interventions

Lenalidomide 3Dexamethasone 3ixazomib 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Radiotherapy 2Calcium Dobesilate 2pomalidomide 1daratumumab 1cc-486 1Thalidomide 1Sodium Selenite 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Immunotherapy, Adoptive 1Gemcitabine 1Drug Combinations 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Plasmacytoma × Peripheral Blood Stem Cell Transplantation × Clear all
NCT02506959 2025-03-18

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡